Introduction
============

Subarachnoid hemorrhage (SAH) is a relatively uncommon and severe type of stroke. As patients are affected by SAH at a mean age of 55 years, they can lose many years of productive life. The rupture of an intracranial aneurysm is the underlying cause in 85% of SAH cases \[[@b1-jos-2019-02103]\]. Approximately 55% of patients survive SAH and regain independent functioning, whereas 19% remain dependent and 26% die \[[@b1-jos-2019-02103]\]. Many survivors of SAH have long-term deficits in cognition, and decreased quality of life \[[@b2-jos-2019-02103]\]. Neuropsychiatric disturbances such as depression, anxiety, post-traumatic stress disorder, and fatigue are not uncommon, yet often neglected in patients with SAH \[[@b3-jos-2019-02103]\].

Depression is common in patients with neurological diseases such as Alzheimer's disease, Parkinson's disease, traumatic brain injury and stroke \[[@b4-jos-2019-02103]\]. Depression is a frequent consequence of head injury, affecting up to 61% of patients. Depression is associated with worse global outcomes, impaired social functioning, difficulty performing activities of daily living, and a lower quality of life \[[@b5-jos-2019-02103]\].

Post-stroke depression contributes to disability and increased mortality following stroke. Depression is increasingly becoming a standard part of post-stroke assessment and rehabilitation \[[@b6-jos-2019-02103]\]. However, there is still a lack of methodically sound psychopharmacological and psychosocial treatment trials on SAH-related depression.

The aims of this systematic review were as follows: (1) to determine the frequency, severity and time course of depression after SAH; (2) to identify the factors associated with the development of depression after SAH, including patients' demographic data, baseline characteristics of SAH, psychological factors including anxiety and cognitive impairment, somatic complications related to SAH (neuroendocrine changes, infarcts, and preexisting and post-SAH medical comorbidities); and (3) to evaluate the impact of depression on patients' quality of life following SAH.

Methods
=======

Literature search
-----------------

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The principal author (W.K.T.) searched the PubMed, EMBASE, PsycINFO, and Ovid Nursing databases on December 5, 2018, using the keywords "depression" or "mood" or "depressive" and "subarachnoid." Two authors (W.K.T. and L.W.) read every title and abstract, obtained the full texts of potentially relevant papers, and applied inclusion and exclusion criteria to each text. Any uncertainties were discussed. W.K.T. also scrutinized the reference lists of included papers to identify further studies.

Inclusion criteria
------------------

Studies were included in the review if they (1) were written in English, (2) were published in peer-reviewed journals, (3) included 10 or more patients who had survived non-traumatic SAH and were older than 18 years \[[@b7-jos-2019-02103]\], and (4) assessed patients for depression using a validated single or multiple item self-report instrument or diagnostic interview.

Exclusion criteria
------------------

Publications were excluded if they were (1) case reports, (2) pediatric studies (patients \<18 years old), (3) dissertations, or (4) articles with no primary data (reviews, editorials letters, etc.), (5) sample size \<40, (6) poor quality (a Strengthening the Report of Observational Studies in Epidemiology \[STROBE\] checklist score ≤13, i.e., 60% of maximum score).

Data extraction
---------------

Two authors (W.K.T. and L.W.) independently extracted the following data from the studies included in the review: study characteristics (aims/objectives, study design, inclusion and exclusion criteria, criteria for and measurement of depression), participants' characteristics (definition of the study population, age, gender, number, ethnicity, and socio-economic status of the patients at the beginning and end of the study, the number of deaths due to SAH, drop-outs, and patients lost to follow-up before the end of study, first or recurrent SAH, severity of SAH, comorbidities and complications) and results (characteristics of patients' subgroups, outcome data, and relationship between depression and patients' characteristics or SAH characteristics and/or outcomes).

Quality assessment
------------------

We used STROBE statement for quality assessment of the included papers \[[@b8-jos-2019-02103]\]. It consists of 22 items. We scored each item 1 point. The maximum possible score is 22.

Data synthesis
--------------

Statistical analyses were performed in Software R (package metaphor & meta, R Foundation for Statistical Computing, Vienna, Austria). The results are presented as a narrative review and are also tabulated. Frist, the weighted proportion of the frequency of depression was calculated. We conducted a metaanalysis of frequency of depression, using the variance-stablizing double-arscine method transformation \[[@b9-jos-2019-02103]\]. Pooled estimates in both the overall (and subgroup) analyses were calculated using the Hartung-Knapp-Sidik-Jonkman method, under the random effect model \[[@b10-jos-2019-02103]\]. Statistical heterogeneity among the trials was assessed, and *P*\<0.1 was considered as statistical significance \[[@b11-jos-2019-02103]\]. Level of heterogeneity was assessed by I2, which describes the percentage of total variation across studies because of heterogeneity rather than chance alone. A randomeffects model for the trials with statistically significant heterogeneity was used. Subgroup analyses were performed according to data collection settings, i.e., interview and questionnaire. Second we conducted a meta-analysis of frequency of depression, using the variance-stablizing double-arscine method transformation \[[@b9-jos-2019-02103]\]. Pooled estimates in both the overall (and subgroup) analyses were calculated using the Hartung-Knapp-Sidik-Jonkman method, under the random effect model \[[@b10-jos-2019-02103]\]. Publication bias was examined by Funnel plot and Egger's regression test. Data from the identical cohorts was reported only once. Where depression was assessed with more than one method in a study, only the results with the most commonly used assessment method were considered. Where data from two or more time points after SAH were available, data from the earlier time point was included in the analysis.

Results
=======

The electronic search identified 2,383 publications potentially eligible for the review. One hundred and six full texts were retrieved for detailed evaluation, of which 51 studies were excluded ([Figure 1](#f1-jos-2019-02103){ref-type="fig"}). Fifty-five studies covering 6,327 patients (range, 40 to 1,181) in 47 cohorts (data from five cohorts were used in 13 publications \[[@b12-jos-2019-02103]-[@b24-jos-2019-02103]\]) met the inclusion criteria ([Table 1](#t1-jos-2019-02103){ref-type="table"}). The majority of studies (46 of 55) included more female than men. Quality of included studies was very different and the STROBE score varied from 14 to 22 ([Supplementary Table 1](#SD1-jos-2019-02103){ref-type="supplementary-material"}).

Fifty-one of 55 studies (93%) used one of the following screening or rating scales to ascertain the presence of depression: Hospital Anxiety Depression Scale (HADS) \[[@b18-jos-2019-02103],[@b19-jos-2019-02103],[@b25-jos-2019-02103]-[@b40-jos-2019-02103]\], Beck Depression Inventory (BDI) \[[@b12-jos-2019-02103]-[@b21-jos-2019-02103],[@b40-jos-2019-02103]-[@b51-jos-2019-02103]\], Center for Epidemiologic Studies Depression (CESD) \[[@b22-jos-2019-02103]-[@b24-jos-2019-02103],[@b52-jos-2019-02103],[@b53-jos-2019-02103]\], Montgomery Åsberg Depression Rating Scale (MADRS) \[[@b54-jos-2019-02103],[@b55-jos-2019-02103]\], Geriatric Depression Scale (GDS) \[[@b56-jos-2019-02103],[@b57-jos-2019-02103]\], International Classification of Diseases 10th Edition (ICD-10)-Symptom-Rating questionnaire \[[@b58-jos-2019-02103]\], Neuropsychiatric Inventory \[[@b3-jos-2019-02103]\], Emotional State Questionnaire \[[@b59-jos-2019-02103]\], Psychological General Well-Being Index \[[@b60-jos-2019-02103]\], and the Zung Depression Scale (ZDS) \[[@b61-jos-2019-02103]\]. Less commonly used measures of depression included the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) axis I disorders \[[@b62-jos-2019-02103]\], clinical interview \[[@b63-jos-2019-02103]\], Cornell personality questionnaire \[[@b64-jos-2019-02103]\], and Depression Skala \[[@b65-jos-2019-02103]\] ([Table 1](#t1-jos-2019-02103){ref-type="table"}).

Twenty-seven studies recruited patients early after SAH and assessed them for depression later. Twenty-six studies recruited patients and collected data at one or more defined time points after SAH (range, 4 days to 10 years) ([Table 1](#t1-jos-2019-02103){ref-type="table"}).

Frequency, severity, and time course of depression after SAH
------------------------------------------------------------

### Frequency of depression after SAH

Thirty-seven studies (n=5,340) reported the frequency of depression after SAH. The frequency ranged widely depending on the assessment method and how long it was performed after the index SAH.

The frequency of depression reported in the 35 studies (n=5,217) that applied rating instruments/questionnaires was in the range of 0% to 61.7%, with a weighted frequency of 28.1%. Depression was assessed at 4 days to 10.1 years after ictus ([Table 2](#t2-jos-2019-02103){ref-type="table"}). The weighted frequency of depression at ≤1 and \>1 year after ictus were 32.2% and 27.3%, respectively. The frequency in the two studies (n=123) that used interviews to diagnose depression found 20% to 25% (weighted proportion=21.6%) of patients depressed ([Table 2](#t2-jos-2019-02103){ref-type="table"}) \[[@b62-jos-2019-02103],[@b63-jos-2019-02103]\].

In the meta-analysis, the overall pooled frequency of depression was 26.3% (95% confidence interval \[CI\], 21.0% to 32.0%). The frequency of depression in the interview and questionnaire studies were 25.0% (95% CI, 12.6% to 39.7%) and 26.3% (95% CI, 20.8% to 32.3%), respectively ([Figure 2](#f2-jos-2019-02103){ref-type="fig"}). The Funnel plot did not suggest any publication bias (*P*=0.434) ([Figure 3](#f3-jos-2019-02103){ref-type="fig"}).

### Severity of depression after SAH

Twelve studies (n=634) assessed the severity of depression using the BDI \[[@b14-jos-2019-02103]-[@b16-jos-2019-02103],[@b18-jos-2019-02103]-[@b21-jos-2019-02103],[@b40-jos-2019-02103],[@b41-jos-2019-02103],[@b44-jos-2019-02103],[@b45-jos-2019-02103],[@b47-jos-2019-02103]\]. The weighted mean BDI value was 9.9 less than 1 year after SAH and 10.1 1-year or more after; these figures indicate mild to moderate depression \[[@b15-jos-2019-02103]\]. Nine studies (n=1,280) evaluated the severity of depression using the HADS \[[@b27-jos-2019-02103]-[@b30-jos-2019-02103],[@b33-jos-2019-02103],[@b34-jos-2019-02103],[@b36-jos-2019-02103]-[@b38-jos-2019-02103]\]. The weighted mean HADS value was 5 less than 1 year after SAH and 5.4 1-year or more after; according to a previous validation study \[[@b66-jos-2019-02103]\], both values can be interpreted as an absence of depression \[[@b27-jos-2019-02103]\]. Less commonly used mood scales were the CESD \[[@b22-jos-2019-02103]-[@b24-jos-2019-02103]\], MADRS \[[@b54-jos-2019-02103],[@b55-jos-2019-02103]\], GDS \[[@b56-jos-2019-02103],[@b57-jos-2019-02103]\], and one study each used the ZDS \[[@b61-jos-2019-02103]\], Depressions Skala \[[@b65-jos-2019-02103]\], Emotional State Questionnaire \[[@b59-jos-2019-02103]\], Cornell Personality Scale \[[@b64-jos-2019-02103]\], and the Psychological General Well-Being Scale \[[@b60-jos-2019-02103]\] ([Tables 1](#t1-jos-2019-02103){ref-type="table"} and [2](#t2-jos-2019-02103){ref-type="table"}, [Supplementary Table 2](#SD2-jos-2019-02103){ref-type="supplementary-material"}).

### Time course of depression after SAH

Eight studies (n=539) assessed depression at more than one time point ([Supplementary Table 3](#SD3-jos-2019-02103){ref-type="supplementary-material"}) \[[@b18-jos-2019-02103],[@b19-jos-2019-02103],[@b23-jos-2019-02103],[@b25-jos-2019-02103],[@b29-jos-2019-02103],[@b41-jos-2019-02103],[@b44-jos-2019-02103],[@b64-jos-2019-02103]\]. In one study (n=113), the proportion of patients with depression increased from 24.8% at discharge to 61.7% at the 12-month follow-up \[[@b44-jos-2019-02103]\]. In another study, 72% of patients with depressive symptoms at 3 months still had symptoms at 2 to 5 years \[[@b41-jos-2019-02103]\]. One study reported an increase in depressive symptoms from 11 months to 12 to 48 months follow-up \[[@b64-jos-2019-02103]\]. On the contrary, five studies (n=261) found no change in depressive symptoms between the first assessment at 3, 6, or 9 months and subsequent follow-up(s) at 6, 9 months, 1, 1.5, 2, or 4 years after SAH \[[@b18-jos-2019-02103],[@b19-jos-2019-02103],[@b23-jos-2019-02103],[@b25-jos-2019-02103],[@b29-jos-2019-02103]\].

In a cross-sectional study, the proportion of patients with depression was not statistically different from patients 2 to 5, 5 to 10, and even more than 10 years after SAH, with 8.3%, 10.7%, and 8.6%, respectively \[[@b37-jos-2019-02103]\]. The weighted frequency of depression was 33% up to a year after SAH and 28% a year or more after \[[@b51-jos-2019-02103],[@b53-jos-2019-02103]\]. There was no relationship between length of follow-up and the severity of depressive symptoms at 39 months after SAH in one study \[[@b67-jos-2019-02103]\].

Association between demographic factors, baseline characteristics of SAH, and depression
----------------------------------------------------------------------------------------

### Demographic characteristics

Two studies explored the association between age and depression after SAH, all with negative findings \[[@b20-jos-2019-02103],[@b40-jos-2019-02103]\]. One study reported a significant correlation between female sex and depression \[[@b54-jos-2019-02103]\]. The association between sex and depression was not significant in the other three studies (n=314) \[[@b34-jos-2019-02103],[@b46-jos-2019-02103]\]. One study found no association between depression and educational level \[[@b65-jos-2019-02103]\]. Another study reported that non-white ethnicity predicted depression ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b53-jos-2019-02103]\].

### Premorbid conditions

Three studies (n=411) examined the role of history of depression prior to SAH. Associations were found between depression and previous mood disorders \[[@b54-jos-2019-02103]\]; lifetime history of major depression, or of anxiety or substance use disorder \[[@b62-jos-2019-02103]\], and self-reported history of depression \[[@b53-jos-2019-02103]\]. One study reported that passive coping predicted post-SAH depressive symptoms ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b41-jos-2019-02103]\]. Other premorbid conditions were examined in three studies.

One found that depression was associated with lifetime psychiatric comorbidity \[[@b62-jos-2019-02103]\]. The second reported that non-fluency in English and nicotine use predicted depression \[[@b53-jos-2019-02103]\]. The third study observed a borderline association between depression and absence of pre-SAH dementia ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b54-jos-2019-02103]\].

Association between clinical features and complications of SAH, comorbidities, biomarkers, and depression
---------------------------------------------------------------------------------------------------------

### Clinical features and complications of SAH

Two studies (n=128) examined the relationship between neurological outcomes and depression, with negative results ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b20-jos-2019-02103],[@b40-jos-2019-02103]\].

Three studies (n=124) compared subtypes of SAH with respect to depression. Depressive symptoms were more common in patients with aneurysmal SAH treated by endovascular treatment or microsurgical clipping than in patients with perimesencephalic SAH \[[@b58-jos-2019-02103]\]. Similarly, aneurysmal SAH patients had a higher mean CESD score and higher rate of depression than their perimensencephalic counterparts in a cohort study \[[@b22-jos-2019-02103]\]. No difference in depressive symptoms between aneurysm versus other bleeding source was observed in a third study ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b20-jos-2019-02103]\].

Two studies (n=274) examined the effect of infarction on the frequency of depression following SAH. SAH-related infarction predicted depression \[[@b53-jos-2019-02103]\]. Parietal and/or frontal infarcts were negatively correlated with depression ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b20-jos-2019-02103]\].

Four studies (n=167) investigated the effect of SAH treatment. Patients treated with clips had more depressive symptoms than those treated with coils \[[@b49-jos-2019-02103]\]. The other three studies (n=135) reported no difference in depressive symptom scores between patients who were treated by surgical clipping and by endovascular coiling \[[@b33-jos-2019-02103],[@b46-jos-2019-02103],[@b50-jos-2019-02103]\]. One study reported no significant association between measures of depression scores and time from admission until surgery \[[@b40-jos-2019-02103]\]. In a second study, rupture of posterior circulation aneurysms was related to a higher level of depression ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b34-jos-2019-02103]\].

### Comorbidities

Seven studies (n=399) examined the impact of cognitive function on post-SAH depression. Two studies reported an association between depressive symptoms and objective and self-rated cognitive function and memory function \[[@b27-jos-2019-02103],[@b57-jos-2019-02103]\]. Another study found depression to be more frequent in cognitively impaired patients \[[@b51-jos-2019-02103]\]. In the fourth study, depressive symptoms were significant determinants of cognitive complaints \[[@b14-jos-2019-02103]\]. In contrast, three studies found no association between depressive symptoms and cognitive performance or impairment \[[@b25-jos-2019-02103],[@b45-jos-2019-02103],[@b65-jos-2019-02103]\]. Two studies explored the role of fatigue in post-SAH depression. Both reported a positive correlation between depressive symptoms and fatigue ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b13-jos-2019-02103],[@b63-jos-2019-02103]\].

Other comorbid conditions were examined in five studies. Severity of depression was correlated with symptoms of posttraumatic stress disorder in two studies \[[@b31-jos-2019-02103],[@b43-jos-2019-02103]\]. A third study found an association between depressive symptoms and overall physical comorbidity \[[@b27-jos-2019-02103]\]. In the fourth study, disability predicted depressive symptoms \[[@b41-jos-2019-02103]\]. Depression was more frequent in patients with reduced working capacity in the fifth study ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b51-jos-2019-02103]\].

### Biological markers

Three studies (n=93) assessed the relationship between biological markers and depression following SAH. One reported an association between hair cortisol level and depressive symptoms \[[@b13-jos-2019-02103]\]. Another found that depression was correlated with basal cortisol value, which also predicted depression \[[@b47-jos-2019-02103]\]. The third study found a positive correlation between apolipoprotein E ε4 (APOE-ε4) levels and depressive symptoms ([Table 3](#t3-jos-2019-02103){ref-type="table"}) \[[@b17-jos-2019-02103]\].

Impact of depression after SAH on patients' lives
-------------------------------------------------

Five studies (n=685) examined the impact of depression on work-related issues. Two studies reported that depression or depressive symptoms were more frequent in patients who were unemployed or with reduced working capacity \[[@b30-jos-2019-02103],[@b51-jos-2019-02103]\]. Lifetime history of major depression and/or post-traumatic stress disorder reduced the likelihood of returning to gainful employment \[[@b62-jos-2019-02103]\]. Two studies concluded that depression or depressive symptoms predicted unemployment ([Table 4](#t4-jos-2019-02103){ref-type="table"}) \[[@b24-jos-2019-02103],[@b61-jos-2019-02103]\].

Seven studies (n=1,642) looked at health-related quality of life (HRQOL) or life satisfaction. Two studies found a negative association between depressive symptoms and HRQOL or satisfaction with life \[[@b16-jos-2019-02103],[@b51-jos-2019-02103]\]. Four studies found that depression and depressive symptoms predicted poor overall HRQOL or the mental health component of HRQOL \[[@b37-jos-2019-02103],[@b44-jos-2019-02103],[@b52-jos-2019-02103],[@b59-jos-2019-02103]\]. One small-scale study reported no association between depression scores and quality of life ([Table 4](#t4-jos-2019-02103){ref-type="table"}) \[[@b65-jos-2019-02103]\].

Three studies (n=399) explored how depression influenced functional outcomes. Depression was correlated with self-rated functional impairment in daily life and with the impact of these impairments \[[@b20-jos-2019-02103]\]. Depression predicted poor functional outcomes a year after SAH \[[@b56-jos-2019-02103]\], but this was not confirmed 3 to 10 years after SAH ([Table 4](#t4-jos-2019-02103){ref-type="table"}) \[[@b26-jos-2019-02103]\].

Other outcomes were assessed in three studies (n=489). Associations were found between depression and problems with leisure and social activities \[[@b30-jos-2019-02103]\], failure to resume previous level of daily life \[[@b61-jos-2019-02103]\], and fatigue ([Table 4](#t4-jos-2019-02103){ref-type="table"}) \[[@b15-jos-2019-02103]\].

Discussion
==========

To the best of our knowledge, this was the first systematic review of depression after SAH. The weighted frequency of depression following SAH was 28.1%. The severity of depressive symptoms was mild to moderate. Depression after SAH seems to run a chronic course and its frequency does not decrease with time. A host of demographic variables, premorbid and comorbid conditions, as well as clinical features and complications of SAH are related to the risk of depression. Depression has negative impacts on the daily lives of patients with SAH.

The weighted frequency of depression of 28% is similar to the frequency of depression after stroke in general (31%) \[[@b68-jos-2019-02103]\]. The frequency of depression in the included studies varied greatly, probably due to differences in the methods of assessment, patients' characteristics, and timing of the assessment. The variation in results was more prominent in studies that used questionnaires (0% to 62%) than in those that used interviews to detect depression (20% to 25%) ([Tables 2](#t2-jos-2019-02103){ref-type="table"} and [4](#t4-jos-2019-02103){ref-type="table"}).

Interviews give a clinical diagnosis whereas questionnaires will assess depressive symptomatology rather than clinical depression. Also, the number of interview studies was considerably smaller.

Longitudinal studies confirmed that depression and depressive symptoms in the later stages of SAH were at least as frequent and severe as in the early stage. Depressive symptoms persisted for long periods after SAH in 72% of patients \[[@b41-jos-2019-02103]\]. Depression after stroke in general is also a chronic condition, with a prevalence and incidence of around 30% and 15% at 1 to 15 years post-stroke \[[@b69-jos-2019-02103]\].

The development of depression after SAH is associated with a variety of factors. The studies included in this review found relationships between depression and female sex, premorbid depression, anxiety, substance use, any psychiatric disorder, and coping styles. Comorbid cognitive impairment, fatigue, post-traumatic stress disorder, and physical disability also increased the risk of depression. The role of the features and complications of SAH in the development of depression was rarely explored, one study suggested that aneurysmal SAH and infarction may be related to depression. The findings on the impact of neurological deficits and treatment modalities for aneurysm repair on depression were inconclusive. Most of the above risk factors have also been found to be related to depression in stroke in general \[[@b70-jos-2019-02103]\]. Further research on psychosocial factors such as pre-stroke life events and the quality of family and social support are warranted \[[@b70-jos-2019-02103]\].

Pituitary dysfunction may occur in up to one in three patients after SAH \[[@b71-jos-2019-02103]\] and could contribute to the development of depression \[[@b72-jos-2019-02103]\]. In support of this theory, an association between low basal cortisol levels and depression has been reported in patients after SAH \[[@b47-jos-2019-02103]\]. One small-scale study reported a possible link between the APOE-ε4 allele and depression \[[@b17-jos-2019-02103]\]. Interestingly, hypercortisolemia, blunted cortisol awakening response \[[@b73-jos-2019-02103]\], and APOE polymorphisms \[[@b74-jos-2019-02103]\] increase the risk of post-stroke depression.

Post-SAH depression was significantly related to functional impairment, unemployment \[[@b75-jos-2019-02103]\] or reduced working capacity, and poor HRQOL. Data on the impact of depression on the costs of hospitalization and mortality related to SAH are lacking \[[@b70-jos-2019-02103]\].

In terms of treatment of post-SAH depression, only one small-scale, open label trial of mindfulness-based psychotherapy has been published. Proper randomized control trials with antidepressants and other treatment modalities are clearly needed. Antidepressants seem to be commonly prescribed in patents with SAH, in a population-based cohort of 940 patients with SAH, 27% had continuous antidepressant use \[[@b76-jos-2019-02103]\]. On the other hand, the use of selective serotonin reuptake inhibitors, a commonly prescribed antidepressant, in general population was associated with increased risk of intracranial hemorrhage, particularly in the first 30 days of use and when used currently with anticoagulants \[[@b77-jos-2019-02103]\]. Antidepressants are effective in the treatment \[[@b78-jos-2019-02103]\] and prevention of post-stroke depression \[[@b79-jos-2019-02103]\], and non-pharmacological treatment modalities including ecosystem-focused therapy, life review therapy, problem solving therapy, meridian acupressure, transcranial magnetic stimulation, music therapy, exercise, light therapy, motivational interviewing, and robotic-assisted neurorehabilitation could also be trialed \[[@b80-jos-2019-02103]\].

This systematic review has several methodological strengths. An extensive search strategy was used so it is unlikely that relevant studies were missed. Two authors extracted pre-specified data independently, thus reducing the chance that any errors in data extraction would have gone undetected. A major limitation is the inclusion only of studies published in English.

There were several methodological shortcomings in the included studies that weakened the robustness of the review. First, the study design was heterogeneous, including longitudinal \[[@b27-jos-2019-02103]\], cross-sectional \[[@b26-jos-2019-02103]\], or retrospective \[[@b32-jos-2019-02103]\] single site cohorts. Second, while most studies recruited hospitalized \[[@b26-jos-2019-02103]\] subjects, some employed clinic \[[@b33-jos-2019-02103],[@b38-jos-2019-02103],[@b42-jos-2019-02103]\], population \[[@b60-jos-2019-02103]\], or support group \[[@b30-jos-2019-02103],[@b31-jos-2019-02103]\] based sampling. Third, a number of studies involved bias sample, such as particular location \[[@b32-jos-2019-02103],[@b54-jos-2019-02103],[@b81-jos-2019-02103]\], investigation \[[@b3-jos-2019-02103]\] or treatment received \[[@b11-jos-2019-02103],[@b37-jos-2019-02103],[@b45-jos-2019-02103]\], or neurological outcome \[[@b65-jos-2019-02103],[@b82-jos-2019-02103]\] of SAH. Fourth, many studies had small sample size. Fifth, the timing of mood assessment various varied from acute \[[@b53-jos-2019-02103],[@b55-jos-2019-02103]\] to chronic stage \[[@b33-jos-2019-02103]\] of SAH recovery. In addition, most of them assessed depression only once; in cross-sectional studies, subjects were assessed at different time point following SAH. Sixth, most studies used scales to measure depression, whereas some employed, a single question \[[@b83-jos-2019-02103]\], or clinical interview \[[@b61-jos-2019-02103],[@b62-jos-2019-02103]\]. Seventh, some authors described the baseline characteristics of SAH but did not relate them to the presence or severity of depression. Eighth, the majority of studies did not measure and adjust for potential confounders, such as personality, level of social support, recent life events, or previous depression with multivariate analysis. Future studies should consider prospective multi-center design, careful and non-selective sampling method, large sample size, assessment of depression at multiple time points with structural psychiatric interview, and detailed measurement and analysis of demographic and clinical characteristics and other possible confounding factors.

Implication for clinicians
--------------------------

Clinicians involved in the long-term care of SAH survivors need to be aware that post-SAH depression is common, runs a chronic course, and has a negative impact on patients' lives. Clinicians should routinely ask about depression when they review SAH patients and they should refer patients with suspected depression for psychological and/or psychiatric evaluation and treatment.

Directions for future research
------------------------------

More longitudinal studies are needed to determine the time course of depression after SAH using standardized diagnostic interviews. More studies assessing the relationship between depression and demographics, premorbid and comorbid conditions and complications of SAH are required to elucidate the relationship between depression and the consequences of SAH. Research on the association between depression and pituitary dysfunction, changes in neurotransmitter metabolism, and disruption of brain circuits after SAH is also warranted to clarify the pathogenesis of post-SAH depression. Finally, randomized controlled clinical trials on potential treatments for SAH-related depression are also needed.

Conclusions
===========

Depression is common after SAH and seems to persist. The development of depression after SAH is associated with a variety of factors. Post-SAH depression had negative impacts on patients' daily life. Further research is needed to clarify its time course and identify the neuroendocrine and neurochemical factors and brain circuits associated with the development of post-SAH depression. Randomized controlled treatment trials targeting SAH-related depression are warranted.
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###### 

Characteristics of the studies included in the systematic review

  Study                                                                                                                                               Design   Participants   Aetiology of SAH                                  Timing after SAH                        Tool used to diagnose depression                               
  --------------------------------------------------------------------------------------------------------------------------------------------------- -------- -------------- ------------------------------------------------- --------------------------------------- ---------------------------------- --------------------------- -----------------------------------------------------------
  Ljunggren et al. (1985) \[[@b63-jos-2019-02103]\]                                                                                                   Cross    40             NR                                                42.5                                    Aneu                               40--45 mo                   Interview
  Hütter et al. (1995) \[[@b20-jos-2019-02103],[@b21-jos-2019-02103]\]                                                                                Cross    58             46 (median)                                       43                                      Aneu                               1--5 yr                     BDI
  Hellawell et al. (1999) \[[@b39-jos-2019-02103]\]                                                                                                   Long     44             49.7±14.6                                         45                                      Aneu                               6 mo (T1)                   HADS
  1 yr (T2)                                                                                                                                                                                                                                                                                                                            
  2 yr (T3)                                                                                                                                                                                                                                                                                                                            
  Fertl et al. (1999) \[[@b51-jos-2019-02103]\]                                                                                                       Cross    40             51 (SD NR)                                        40                                      Aneu                               Average 22 mo (range, NR)   BDI
  Carter et al. (2000) \[[@b61-jos-2019-02103]\]                                                                                                      Cross    182            52 (SD NR)                                        NR                                      Aneu                               1--5 yr                     ZDS
  Powell et al. (2002) \[[@b18-jos-2019-02103]\] and Powell et al. (2004) \[[@b19-jos-2019-02103]\]                                                   Long     52             46.9±10.4                                         33                                      Aneu                               3 mo (T1)                   BDI & HADS
  9 mo (T2)                                                                                                                                                                                                                                                                                                                            
  18 mo (T3)                                                                                                                                                                                                                                                                                                                           
  Fontanella et al. (2003) \[[@b50-jos-2019-02103]\]                                                                                                  Long     37             55.3±8.8                                          35                                      Aneu                               6 mo                        BDI
  Bellebaum et al. (2004) \[[@b49-jos-2019-02103]\]                                                                                                   Long     32             54.4±12.5                                         NR                                      Aneu                               23--28 mo                   BDI
  Morris et al. (2004) \[[@b40-jos-2019-02103]\]                                                                                                      Cross    70             45.2±15.2                                         39                                      Aneu (81%)                         14--23 mo                   BDI & HADS
  Salmond et al. (2006) \[[@b48-jos-2019-02103]\]                                                                                                     Cross    20             58.6±2.1                                          20                                      Aneu                               14--99 mo                   BDI
  Wermer et al. (2007) \[[@b38-jos-2019-02103]\]                                                                                                      Cross    610            54.3±9.0                                          36                                      Aneu                               2.3--18.8 yr                HADS
  Kreitschmann-Andermahr et al. (2007) \[[@b47-jos-2019-02103]\]                                                                                      Cross    40             43.8 (SD NR)                                      NR                                      Aneu                               12--66 mo                   BDI
  Preiss et al. (2007) \[[@b46-jos-2019-02103]\]                                                                                                      Long     75             45.7 (SD NR)                                      33                                      Aneu                               1 yr                        BDI
  Orbo et al. (2008) \[[@b45-jos-2019-02103]\]                                                                                                        Long     42             48 (SD NR)                                        40.4                                    Aneu                               1 yr                        BDI
  Visser-Meily et al. (2009) \[[@b36-jos-2019-02103]\]                                                                                                Cross    141            54.1±12.3                                         33.3                                    Aneu                               2--4 yr                     HADS
  Haug et al. (2009) \[[@b55-jos-2019-02103]\]                                                                                                        Long     46             53 (median)                                       37                                      Aneu                               1 yr                        MADRS
  King et al. (2009) \[[@b37-jos-2019-02103]\]                                                                                                        Long     178            54.7±12.6                                         26                                      Aneu                               NR                          HADS
  Mukerji et al. (2010) \[[@b35-jos-2019-02103]\]                                                                                                     Cross    77             54.3±10.8                                         32.5                                    Aneu (84%)                         12--266 mo                  HADS
  Passier et al. (2010) \[[@b14-jos-2019-02103]\], Passier et al. (2011) \[[@b15-jos-2019-02103]\], Passier et al. (2012) \[[@b16-jos-2019-02103]\]   Long     111            52.8±13.0                                         18                                      Aneu                               3 mo                        BDI
  Meyer et al. (2010) \[[@b44-jos-2019-02103]\]                                                                                                       Long     113            54.4±14.1                                         32.7                                    Aneu                               At discharge (T1)           BDI
  12 mo (T2)                                                                                                                                                                                                                                                                                                                           
  Caeiro et al. (2011) \[[@b54-jos-2019-02103]\]                                                                                                      Long     108            53.5±14.2                                         30                                      Aneu (56%)                         ≤4 day                      MADRS
  Alfieri et al. (2008) \[[@b17-jos-2019-02103]\]                                                                                                     Long     38             44.3±13.7                                         42                                      Aneu (47%)                         On admission (T1)           BDI
  1 mo (T2)                                                                                                                                                                                                                                                                                                                            
  1 yr (T3)                                                                                                                                                                                                                                                                                                                            
  3 yr (T4)                                                                                                                                                                                                                                                                                                                            
  5 yr (T5)                                                                                                                                                                                                                                                                                                                            
  Hedlund et al. (2011) \[[@b62-jos-2019-02103]\]                                                                                                     Long     83             52±9                                              36                                      NR                                 10 day (T1)                 Structured clinical interview for DSM-IV axis I disorders
  7 mo (T2)                                                                                                                                                                                                                                                                                                                            
  Wong et al. (2012) \[[@b57-jos-2019-02103]\]                                                                                                        Long     90             45±11                                             76                                      Aneu                               3 mo                        GDS
  Latimer et al. (2013) \[[@b33-jos-2019-02103]\]                                                                                                     Cross    23             52.7 (SD NR)                                      NR                                      Aneu                               40--45 mo                   HADS
  von Vogelsang et al. (2013) \[[@b34-jos-2019-02103]\]                                                                                               Cross    217            50.6±12                                           29                                      Aneu                               8.8--12 yr                  HADS
  Kreiter et al. (2013) \[[@b53-jos-2019-02103]\]                                                                                                     Long     216            51.2±13.8                                         36                                      Aneu (87%)                         3 mo (T1)                   CESD
  1 yr (T2)                                                                                                                                                                                                                                                                                                                            
  Wong et al. (2013) \[[@b56-jos-2019-02103]\]                                                                                                        Long     120            51 (median)                                       68                                      Aneu                               1 yr                        GDS
  Vetkas et al. (2013) \[[@b59-jos-2019-02103]\]                                                                                                      Cross    114            54±13                                             32                                      Aneu                               1--10 yr                    Emotional State Questionnaire
  Noble et al. (2014) \[[@b32-jos-2019-02103]\]                                                                                                       Cross    414            44.6 (SD NR)                                      25                                      Aneu (68.4%)                       0--34 yr                    HADS
  Wong et al. (2014) \[[@b3-jos-2019-02103]\]                                                                                                         Cross    103            55±10                                             29                                      Aneu                               1--4 yr                     Neuropsychiatric inventory
  Gill et al. (2015) \[[@b31-jos-2019-02103]\]                                                                                                        Cross    93             49.67±10.05                                       20.43                                   NR                                 2--58 mo                    HADS
  Hütter et al. (2014) \[[@b43-jos-2019-02103]\]                                                                                                      Cross    45             47.1±10.7                                         44                                      Aneu (64%)                         3--5 yr                     BDI
  Boerboom et al. (2014) \[[@b22-jos-2019-02103]\] and Boerboom et al. (2016) \[[@b23-jos-2019-02103],[@b24-jos-2019-02103]\]                         Long     76             53.8±11.5                                         31.6                                    Aneu                               0.4 yr (T1)                 CESD
  3.9 yr (T2)                                                                                                                                                                                                                                                                                                                          
  von Vogelsang et al. (2015) \[[@b29-jos-2019-02103]\]                                                                                               Long     88             52.6±14.2                                         34.1                                    Aneu                               6 mo (T1)                   HADS
  1 yr (T2)                                                                                                                                                                                                                                                                                                                            
  2 yr (T3)                                                                                                                                                                                                                                                                                                                            
  Buunk et al. (2015) \[[@b30-jos-2019-02103]\]                                                                                                       Cross    200            58.7 (SD NR)                                      36.5                                    Aneu                               2--10 yr                    HADS
  Brand et al. (2015) \[[@b65-jos-2019-02103]\]                                                                                                       Long     21             58.8 (SD NR)                                      19                                      Aneu                               5--9 mo                     Depression Skala
  Scherfler et al. (2016) \[[@b28-jos-2019-02103]\]                                                                                                   Long     14             46.1±12                                           43                                      Aneu (36%)                         1 yr                        HADS
  Gerber et al. (2016) \[[@b42-jos-2019-02103]\]                                                                                                      Cross    15             52.7±9.8                                          27                                      Aneu                               44 mo                       BDI
  Taufique et al. (2016) \[[@b52-jos-2019-02103]\]                                                                                                    Long     1181           52.3±12.8                                         NR                                      NR                                 1 yr                        CESD
  Kronvall et al. (2016) \[[@b60-jos-2019-02103]\]                                                                                                    Long     51             NR                                                NR                                      Aneu                               3--6 mo (T1)                Psychological general well-being
  6--12 mo (T2)                                                                                                                                                                                                                                                                                                                        
  12--24 mo (T3)                                                                                                                                                                                                                                                                                                                       
  Pačić-Turk et al. (2016) \[[@b64-jos-2019-02103]\]                                                                                                  Long     72             46±9.2                                            39                                      Aneu                               11 mo (T1)                  Cornell personality questionnaire
  12--48 mo (T2)                                                                                                                                                                                                                                                                                                                       
  Colledge et al. (2017) \[[@b12-jos-2019-02103],[@b13-jos-2019-02103]\]                                                                              Cross    15             57.3±8.9                                          27                                      Aneu                               44 mo                       BDI
  Ackermark et al. (2017) \[[@b41-jos-2019-02103]\]                                                                                                   Long     93             50.3±11.8                                         19.4                                    Aneu                               3 mo (T1)                   BDI
  1 yr (T2)                                                                                                                                                                                                                                                                                                                            
  2--5 yr (T3)                                                                                                                                                                                                                                                                                                                         
  Buunk et al. (2018) \[[@b26-jos-2019-02103]\]                                                                                                       Cross    221            57.0±10.0 (Aneu group), 55.4±10.2 (other group)   31.3 (Aneu group), 58.2 (other group)   Aneu (75%)                         3--10 yr                    HADS
  Tölli et al. (2018) \[[@b25-jos-2019-02103]\]                                                                                                       Long     45             57.4±9.9                                          22.9                                    NR                                 3 mo (T1)                   HADS
  6 mo (T2)                                                                                                                                                                                                                                                                                                                            
  12 mo (T3)                                                                                                                                                                                                                                                                                                                           
  Bründl et al. (2018) \[[@b58-jos-2019-02103]\]                                                                                                      Long     21             42.0--59.8 (mean)                                 33.3--50                                Aneu (71%)                         11--35 day (T1)             ICD-10-Symptom-Rating Questionnaire
  6 mo (T2)                                                                                                                                                                                                                                                                                                                            

SD, standard deviation; SAH, subarachnoid hemorrhage; Cross, cross-sectional; NR, not reported; Aneu, aneurysmal; BDI, Beck Depression Inventory; Long, longitudinal; HADS, Hospital Anxiety Depression Scale; ZDS, Zung Self-rating Depression Scale; MADRS, Montgomery Åsberg Depression Rating Scale; DSMIV, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; GDS, Geriatric Depression Scale; CESD, Center for Epidemiologic Studies Depression; ICD-10, International Classification of Diseases 10th Edition.

###### 

Studies of frequency and/or severity of depression after SAH

  Study                                                      Study design and setting                                                                                                                            Timing after SAH                                                                                                Cut off point                         Proportion of participants with depression (%)   Depressive symptom scores (mean±SD)   Limitations    
  ---------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------ ------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Depression measured by rating instruments/questionnaires                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                             Alfieri et al. (2008) \[[@b17-jos-2019-02103]\]                                                                                                     Longitudinal study, hospitalized patients                                                                       On admission (T1)                     NR                                               NR                                    T1: 17.1±6.5   Small sample size
  1 mo (T2)                                                  T2: 22.1±3.6                                                                                                                                                                                                                                                                                                                                                                                                    
  1 yr (T3)                                                  T3: 19.9±4.8                                                                                                                                                                                                                                                                                                                                                                                                    
  3 yr (T4)                                                  T4: 14.3±3.8                                                                                                                                                                                                                                                                                                                                                                                                    
  5 yr (T5)                                                  T5: 13.2±3.8                                                                                                                                                                                                                                                                                                                                                                                                    
                                                             Caeiro et al. (2011) \[[@b54-jos-2019-02103]\]                                                                                                      Prospective study, consecutive admissions to an academic neurosurgery center                                    ≤4 day                                MADRS ≥7                                         45                                    9.2±7.3        Sample biased towards SAH of mild severity, depression not assessed at subacute and chronic stage of SAH
                                                             Meyer et al. (2010) \[[@b44-jos-2019-02103]\]                                                                                                       Longitudinal study                                                                                              At discharge (T1)                     BDI \>10                                         T1: 24.8                              NR             Patients with aphasia excluded, possible confounders not measured.
  12 mo (T2)                                                 T2: 61.7                                                                                                                                                                                                                                                                                                                                                                                                        
                                                             Passier et al. (2010) \[[@b14-jos-2019-02103]\], Passier et al. (2011) \[[@b15-jos-2019-02103]\], Passier et al. (2012) \[[@b16-jos-2019-02103]\]   Cross-sectional study, all subjects treated with clipping or coiling                                            3 mo                                  BDI ≥10                                          40                                    9.6±6.9        Nursing home patients not included.
                                                             Powell et al. (2002) \[[@b18-jos-2019-02103]\] and Powell et al. (2004) \[[@b19-jos-2019-02103]\]                                                   Cross-sectional study, consecutive admissions to a neurovascular service                                        3 mo (T1)                             BDI \>10                                         T1: 9.1                               T1: 9.6±6.2    Small sample size
  9 mo (T2)                                                  T2: 11.4                                                                                                                                            T2: 9.2±6.9                                                                                                                                                                                                                                                 
  18 mo (T3)                                                 T3: 16.3                                                                                                                                            T3: 9.4±7.3                                                                                                                                                                                                                                                 
                                                             Ackermark et al. (2017) \[[@b41-jos-2019-02103]\]                                                                                                   Longitudinal study, subjects recruited from a clinic                                                            3 mo (T1)                             BDI ≥10                                          T1: 39                                T1: 8.9±7.0    Nursing home patients not included, no data of previous mental health problems, locus of control, optimism or social support, self-report of depressive symptoms.
  1 yr (T2)                                                  T2: 41                                                                                                                                              T2: 9.3±7.1                                                                                                                                                                                                                                                 
  2--5 yr (T3)                                               T3: 54                                                                                                                                              T3: 11.2±8.0                                                                                                                                                                                                                                                
                                                             Kronvall et al. (2016) \[[@b60-jos-2019-02103]\]                                                                                                    Prospective study in an academic neurosurgery unit                                                              3--6 mo (T1)                          NR                                               NR                                    T1: 15.0±3.5   Small sample size, validity of the mood assessment uncertain
  6--12 mo (T2)                                              T2: 15.3±2.9                                                                                                                                                                                                                                                                                                                                                                                                    
  12--24 mo (T3)                                             T3: 15.8±2.9                                                                                                                                                                                                                                                                                                                                                                                                    
                                                             Wong et al. (2012) \[[@b57-jos-2019-02103]\]                                                                                                        Prospective multi-center study of consecutive admissions                                                        3 mo                                  NR                                               NR                                    7 (median)     Lack of gold standard measure of depression
                                                             Kreiter et al. (2013) \[[@b53-jos-2019-02103]\]                                                                                                     Prospective study, consecutive admissions to an academic neurosurgery center                                    3 mo (T1)                             CESD ≥16                                         T1: 38                                NR             Less severely affected subjects more likely to complete follow-up, subjects treated for SAH a decade ago, confounders not considered.
  1 yr (T2)                                                  T2: 33                                                                                                                                                                                                                                                                                                                                                                                                          
                                                             Boerboom et al. (2014) \[[@b22-jos-2019-02103]\] and Boerboom et al. (2016) \[[@b23-jos-2019-02103],[@b24-jos-2019-02103]\]                         Prospective study, consecutive admissions to an academic neurosurgery center                                    0.4 yr (T1)                           CESD ≥16                                         T2: 26.7                              T1: 13.7±1.2   Subjects assessed at different time points following SAH.
  3.9 yr (T2)                                                T2: 11.9±1.2                                                                                                                                                                                                                                                                                                                                                                                                    
                                                             Fontanella et al. (2003) \[[@b50-jos-2019-02103]\]                                                                                                  Cross-sectional study, all subjects had treated anterior communicating artery bleeding aneurysm                 6 mo                                  NR                                               NR                                    13.8 (SD NR)   Small sample size, limited generalizability to patients with other type of SAH
                                                             von Vogelsang et al. (2015) \[[@b29-jos-2019-02103]\]                                                                                               Longitudinal study, hospitalized subjects                                                                       6 mo (T1)                             HADS ≥8                                          T1: 25.0                              T1: 5.0        No data on previous history of depression or use of antidepressants during the follow-up period
  1 yr (T2)                                                  T2: 27.6                                                                                                                                            T2: 4.0                                                                                                                                                                                                                                                     
  2 yr (T3)                                                  T3: 29.4                                                                                                                                            T3: 5.0 (median)                                                                                                                                                                                                                                            
                                                             Hellawell et al. (1999) \[[@b39-jos-2019-02103]\]                                                                                                   Longitudinal study, subjects recruited from a neurosurgical unit                                                6 mo (T1)                             NR                                               T1: 8                                 NR             Small sample size, high attrition rate
  1 yr (T2)                                                  T2: 9                                                                                                                                                                                                                                                                                                                                                                                                           
  2 yr (T3)                                                  T3: 5                                                                                                                                                                                                                                                                                                                                                                                                           
                                                             Brand et al. (2015) \[[@b65-jos-2019-02103]\]                                                                                                       Case-control study, all subjects had treated SAH                                                                5--9 mo                               NR                                               NR                                    1.42±0.29      Small sample size, validity of the mood assessment uncertain, confounders not measured.
                                                             Pačić-Turk et al. (2016) \[[@b64-jos-2019-02103]\]                                                                                                  Prospective study in an academic neurosurgery unit                                                              11 mo (T1)                            NR                                               NR                                    T1: 1.93       Modest sample size, validity of the mood assessment uncertain
  12--48 mo (T2)                                             T2: 2.65                                                                                                                                                                                                                                                                                                                                                                                                        
                                                             Scherfler et al. (2016) \[[@b28-jos-2019-02103]\]                                                                                                   Longitudinal study, subjects recruited from a neurological intensive care unit                                  1 yr                                  HADS \>10                                        0                                     1 (median)     Small sample size, selected inclusion of patients without visually detectable structural lesions on MRI
                                                             Tölli et al. (2018) \[[@b25-jos-2019-02103]\]                                                                                                       Longitudinal study, subjects recruited from a neruointensive care unit                                          1 yr                                  HADS ≥8                                          23                                    NR             Single center study, small sample size
                                                             Orbo et al. (2008) \[[@b45-jos-2019-02103]\]                                                                                                        Longitudinal study, all subjects treated with clipping                                                          1 yr                                  BDI ≥14                                          5                                     6 (SD NR)      Small sample size
                                                             Preiss et al. (2007) \[[@b46-jos-2019-02103]\]                                                                                                      Longitudinal study, all subjects treated with coiling or clipping                                               1 yr                                  NR                                               NR                                    9.4            Relative small sample size, potential selection bias
                                                             Haug et al. (2009) \[[@b55-jos-2019-02103]\]                                                                                                        Prospective study, all subjects treated for anterior or middle cerebral artery bleeding aneurysm                1 yr                                  NR                                               NR                                    5.5 (SD NR)    Small sample size, subjects with other locations of aneurysms excluded.
                                                             Taufique et al. (2016) \[[@b52-jos-2019-02103]\]                                                                                                    Prospective study, consecutive admissions to an academic neurosurgery center                                    1 yr                                  CESD ≥16                                         33.3                                  NR             Poor grade patients more likely to be lost to follow-up.
                                                             Mukerji et al. (2010) \[[@b35-jos-2019-02103]\]                                                                                                     Retrospective subject recruitment, all subjects received an angiogram                                           Median 13 mo (range, 12--266)         NR                                               13                                    NR             Subjects recruited at different time points following SAH, small sample size
                                                             Morris et al. (2004) \[[@b40-jos-2019-02103]\]                                                                                                      Cross-sectional study, method and site of recruitment not reported                                              Average 16 mo (range, 14--23)         BDI ≥10                                          50                                    NR             Small sample size, opportunity samples, subjects recruited at different time points following SAH
                                                             Gill et al. (2015) \[[@b31-jos-2019-02103]\]                                                                                                        Cross-sectional study, subjects recruited from neuropsychology services, charities and online support network   Average 21.1 mo (range, 2--58)        HADS ≥8                                          51                                    NR             No data on those refused to participate, self-report data of SAH, severity of injury not recorded, subjects, recruited at different time points following SAH.
                                                             Fertl et al. (1999) \[[@b51-jos-2019-02103]\]                                                                                                       Cross-sectional study, all subjects treated for SAH                                                             Average 22 mo (range, NR)             ≥12                                              28                                    NR             Small sample size, subjects recruited at different time points following SAH
                                                             Kreitschmann-An-dermahr et al. (2007) \[[@b47-jos-2019-02103]\]                                                                                     Cross-sectional study, method and site of recruitment not reported                                              Average 27.3 mo (range, 12--66)       BDI \>10                                         37.5                                  8.33±5.85      Small sample size, subjects recruited at different time points following SAH
                                                             Wong et al. (2014) \[[@b3-jos-2019-02103]\]                                                                                                         Cross-sectional four centers study, hospitalized subjects                                                       Average NR (range, 1--4 yr)           \-                                               13                                    NR             Attrition, subjects recruited at different time points following SAH, confounders not measured, reporting bias
                                                             Visser-Meily et al. (2009) \[[@b36-jos-2019-02103]\]                                                                                                Cross-sectional study, all subjects had been treated with coiling or clipping                                   Average 3 yr (range, 2--4)            HADS ≥8                                          23                                    4.8±3.9        Selection bias as only patients still alive included, subjects recruited at different time points following SAH.
                                                             Noble et al. (2014) \[[@b32-jos-2019-02103]\]                                                                                                       Cross-sectional study, subjects recruited from support groups                                                   Median 3 yr (range, 1--5)             HADS ≥8                                          45.2                                  NR             Only patients had access to internet included, no data on those refused to participate, lack of psychiatric interviews, self-report data of SAH details, subjects recruited at different time points following SAH.
                                                             Hütter et al. (1995) \[[@b20-jos-2019-02103],[@b21-jos-2019-02103]\]                                                                                Cross-sectional study, all subjects operated for SAH                                                            Median 3 yr (range, 1--5)             BDI \>10                                         30                                    NR             Small sample size, subjects recruited at different time points following SAH, excluded subjects had worse SAH grading.
                                                             Carter et al. (2000) \[[@b61-jos-2019-02103]\]                                                                                                      Cross-sectional study, consecutive admissions to a tertiary medical center                                      Average NR (range, 1--5 yr)           ZDS ≥50                                          36                                    45.6 (SD NR)   Subjects recruited at different time points following SAH
                                                             Latimer et al. (2013) \[[@b33-jos-2019-02103]\]                                                                                                     Retrospective subject recruitment, all subjects had anterior circulatory area SAH                               40--45 mo                             NR                                               NR                                    6.7            Retrospective subject recruitment, selective sample, small sample size
                                                             Colledge et al. (2017) \[[@b12-jos-2019-02103],[@b13-jos-2019-02103]\] and Gerber et al. (2016) \[[@b42-jos-2019-02103]\]                           Cross-sectional study, almost all subjects treated with clipping                                                44 mo                                 NR                                               NR                                    8.9±6.6        Small sample size, subjects recruited at different time points following SAH, lack of psychiatric interview
                                                             Vetkas et al. (2013) \[[@b59-jos-2019-02103]\]                                                                                                      Retrospective study of a single academic center                                                                 Average 4.5 yr (range, 1--10)         GDS ≥12                                          30                                    8.4±6.9        Retrospective study, subjects assessed at different time points following SAH
                                                             Buunk et al. (2015) \[[@b30-jos-2019-02103]\]                                                                                                       Cross-sectional study, all subjects had been treated by coiling or clipping                                     Average 4.6 yr (range, 2--10)         HADS ≥8                                          23                                    4.2±4.3        Selective sample, subjects recruited at different time points following SAH
                                                             Boerboom et al. (2017) \[[@b27-jos-2019-02103]\]                                                                                                    Cross-sectional study, hospitalized subjects                                                                    Average 4.7 yr (range, NR)            HADS ≥8                                          15.2                                  3.5 (SD NR)    Selection bias, small sample size, subjects recruited at different time points following SAH
                                                             Salmond et al. (2006) \[[@b48-jos-2019-02103]\]                                                                                                     Cross-sectional study, method and site of recruitment not reported                                              Average 68 mo (range, 14--99)         NR                                               NR                                    6.5±1.4        Small sample size, subjects recruited at different time points following SAH
                                                             Wermer et al. (2007) \[[@b38-jos-2019-02103]\]                                                                                                      Cross-sectional study, all subjects treated with clipping                                                       Average 8.9 yr (range, 2.3--18.8)     HADS \>10                                        9.4                                   6.2±3.1        Only patients treated with clipping and regained functional independence included, relative young age of the subjects, subjects recruited at different time points following SAH.
                                                             von Vogelsang et al. (2013) \[[@b34-jos-2019-02103]\]                                                                                               Retrospective subject recruitment, subjects recruited from a neurosurgical clinic                               Average 10.1 yr (range, 8.8--12)      HADS ≥8                                          23.5                                  4.0 (median)   Subjects recruited at different time points following SAH, no data on previous history of depression or use of antidepressants during the followup period
                                                             King et al. (2009) \[[@b37-jos-2019-02103]\]                                                                                                        Cross-sectional study, subjects recruited from neurosurgery clinics                                             NR                                    HADS \>10                                        9                                     4.8±3.4        A single academic center study, some eligible patients not participated, Caucasians over-represented
  Depression measured by interview                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                             Ljunggren et al. (1985) \[[@b63-jos-2019-02103]\]                                                                                                   Cross-sectional study, all subjects had treated SAH and good neurological recovery                              Average 3.5 yr (range, 14 mo--7 yr)   \-                                               25                                    NR             Attrition, sampling bias, subjects recruited at different time points following SAH, self-report of depression
                                                             Hedlund et al. (2011) \[[@b62-jos-2019-02103]\]                                                                                                     Prospective study, all subjects had treated SAH and good neurological outcome                                   7 mo                                  \-                                               21                                    NR             Attrition, sampling bias

SAH, subarachnoid hemorrhage; SD, standard deviation; NR, not reported; MADRS, Montgomery Åsberg Depression Rating Scale; BDI, Beck Depression Inventory; CESD, Center for Epidemiologic Studies Depression; HADS, Hospital Anxiety Depression Scale; MRI, magnetic resonance imaging; ZDS, Zung Depression Scale; GDS, Geriatric Depression Scale.

###### 

Studies of associations between clinical features and complications of subarachnoid hemorrhage, comorbidities, biomarkers, and depression

  Study                                        Risk factors                                                           Associations with depression     Confounders controlled using multivariate analysis                                                                                                                                                                                                              
  -------------------------------------------- ---------------------------------------------------------------------- -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----
  Demographic characteristics                                                                                                                                                                                                                                                                                                                                                                                          
                                               Hütter et al. (1995) \[[@b20-jos-2019-02103]\]                         Age                              No association                                                                                                                                                                                                                                                  No
                                               Morris et al. (2004) \[[@b40-jos-2019-02103]\]                         Age                              No association                                                                                                                                                                                                                                                  No
                                               Caeiro et al. (2011) \[[@b54-jos-2019-02103]\]                         Sex                              Female sex (*P*=0.003)                                                                                                                                                                                                                                          No
                                               Preiss et al. (2007) \[[@b46-jos-2019-02103]\]                         Sex                              No association                                                                                                                                                                                                                                                  No
                                               von Vogelsang et al. (2013) \[[@b34-jos-2019-02103]\]                  Sex                              No association                                                                                                                                                                                                                                                  No
                                               Kreiter et al. (2013) \[[@b53-jos-2019-02103]\]                        Ethnicity                        Non-white ethnicity, (OR, 2.7; 95% Cl, 1.4--5.4; *P*=0.005); non-fluency in English (OR, 3.7; 95% Cl, 1.7--8.2; *P*=0.001)                                                                                                                                      No
                                               Brand et al. (2015) \[[@b65-jos-2019-02103]\]                          Education                        No association                                                                                                                                                                                                                                                  No
  Premorbid conditions                                                                                                                                                                                                                                                                                                                                                                                                 
                                               Caeiro et al. (2011) \[[@b54-jos-2019-02103]\]                         Psychiatric history              Past mood disorder (*P*=0.007), absence of pre-SAH dementia (*P*=0.05)                                                                                                                                                                                          No
                                               Kreiter et al. (2013) \[[@b53-jos-2019-02103]\]                        Psychiatric history              History of depression (OR, 3.1; 95% Cl, 1.2--7.6; *P*=0.016)                                                                                                                                                                                                    Yes
                                               Hedlund et al. (2011) \[[@b62-jos-2019-02103]\]                        Psychiatric history              Lifetime affective disorder (OR, 11.9; 95% Cl, 3.0--46, *P*=0.001), anxiety disorder (OR, 6.5; 95% Cl, 1.6--26; *P*=0.008), substance use disorder (OR, 9.8; 95% Cl, 1.5--66; *P*=0.019), or any psychiatric disorders (OR, 14.1; 95% Cl, 3.0--47; *P*=0.001)   Yes
                                               Kreiter et al. (2013) \[[@b53-jos-2019-02103]\]                        Psychiatric history              Nicotine use (OR, 2.4; 95% Cl, 1.3--4.5; *P*=0.006)                                                                                                                                                                                                             Yes
                                               Ackermark et al. (2017) \[[@b41-jos-2019-02103]\]                      Premorbid personality traits     Passive coping was correlated with depressive symptoms (ρ=0.576, *P*\<0.001).                                                                                                                                                                                   Yes
  Clinical features and complications of SAH                                                                                                                                                                                                                                                                                                                                                                           
                                               Hütter et al. (1995) \[[@b20-jos-2019-02103],[@b21-jos-2019-02103]\]   Neurological outcomes            No association                                                                                                                                                                                                                                                  No
                                               Morris et al. (2004) \[[@b40-jos-2019-02103]\]                         Neurological outcomes            No association                                                                                                                                                                                                                                                  No
                                               Bründl et al. (2018) \[[@b58-jos-2019-02103]\]                         subtypes of SAH                  Depression symptoms were more common in aneurysmal SAH patients treated with microsurgury and endovascular aneurysm occlusion than those with perimensencephalic SAH (*P*=0.035 and *P*=0.016 respectively).                                                    No
                                               Boerboom et al. (2014) \[[@b22-jos-2019-02103]\]                       subtypes of SAH                  Aneurysmal SAH patients had a higher mean CESD score (13.9±8.7 vs. 5.0±4.9, *P*=0.006) and higher rate of depression (44.4% vs. 0%, *P*=0.035) than perimensencephalic SAH.                                                                                     No
                                               von Vogelsang et al. (2013) \[[@b34-jos-2019-02103]\]                  Location of aneurysms            Rupture of posterior circulation aneurysms, compared to anterior circulation aneurysums, was related to a higher level of depression (*P*=0.036).                                                                                                               No
                                               Hütter et al. (1995) \[[@b20-jos-2019-02103]\]                         subtypes of SAH                  No association                                                                                                                                                                                                                                                  No
                                               Kreiter et al. (2013) \[[@b53-jos-2019-02103]\]                        Infarctions                      SAH-related infarction predicted depression (OR, 2.1; 95% Cl, 1.1--4.0; *P*=0.026).                                                                                                                                                                             Yes
                                               Hütter et al. (1995) \[[@b21-jos-2019-02103]\]                         Infarctions                      Parietal and/or frontal infarcts were negatively correlated with depression (n=58; F=5.03, t=2.57, *P*=0.03).                                                                                                                                                   No
                                               Bellebaum et al. (2004) \[[@b49-jos-2019-02103]\]                      SAH treatment                    Patients treated with clips had more depressive symptoms than those treated with coils (U=73.50; *P*=0.039).                                                                                                                                                    No
                                               Preiss et al. (2007) \[[@b46-jos-2019-02103]\]                         SAH treatment                    No difference between clips and coils                                                                                                                                                                                                                           No
                                               Fontanella et al. (2003) \[[@b50-jos-2019-02103]\]                     SAH treatment                    No difference between clips and coils                                                                                                                                                                                                                           No
                                               Latimer et al. (2013) \[[@b33-jos-2019-02103]\]                        SAH treatment                    No difference between clips and coils                                                                                                                                                                                                                           No
  Comorbidities                                                                                                                                                                                                                                                                                                                                                                                                        
                                               Boerboom et al. (2017) \[[@b27-jos-2019-02103]\]                       Cognitive function               Self-rated cognitive function (r=0.372) and memory function (r=--0.427)                                                                                                                                                                                         No
                                               Fertl et al. (1999) \[[@b51-jos-2019-02103]\]                          Cognitive function               Cognitive impairment (*P*\<0.01)                                                                                                                                                                                                                                No
                                               Passier et al. (2010) \[[@b14-jos-2019-02103]\]                        Cognitive function               depressive symptoms predicted cognitive complaints (β=0.40, *P*\<0.001)                                                                                                                                                                                         Yes
                                               Wong et al. (2012) \[[@b57-jos-2019-02103]\]                           Cognitive function               MoCA (Kendall's tau b coefficient 0.191; *P*=0.027) and MMSE (Kendall's tau b coefficient 0.198; *P*=0.024)                                                                                                                                                     No
                                               Brand et al. (2015) \[[@b65-jos-2019-02103]\]                          Cognitive function               No association                                                                                                                                                                                                                                                  No
                                               Tölli et al. (2018) \[[@b25-jos-2019-02103]\]                          Cognitive function               No association                                                                                                                                                                                                                                                  No
                                               Orbo et al. (2008) \[[@b45-jos-2019-02103]\]                           Cognitive function               No association                                                                                                                                                                                                                                                  No
                                               Ljunggren et al. (1985) \[[@b63-jos-2019-02103]\]                      Fatigue                          Correlated with depressive symptoms (r=0.597)                                                                                                                                                                                                                   No
                                               Buunk et al. (2018) \[[@b26-jos-2019-02103]\]                          Fatigue                          Correlated with depressive symptoms (r=0.58)                                                                                                                                                                                                                    No
                                               Hütter et al. (2014) \[[@b43-jos-2019-02103]\]                         Post-traumatic stress disorder   Severity of depression was correlated with scores on the IES avoidance and intrusion subscales (r=0.45 and r=0.52, respectively).                                                                                                                               No
                                               Gill et al. (2015) \[[@b31-jos-2019-02103]\]                           Post-traumatic stress disorder   Higher rate of depression predicted greater symptoms of post-traumatic stress disorder (β=0.38, t=5.74, *P*\<0.001).                                                                                                                                            Yes
                                               Boerboom et al. (2017) \[[@b27-jos-2019-02103]\]                       Physical comorbidity             Correlated with depressive symptoms (r=0.419)                                                                                                                                                                                                                   No
  Functioning                                                                                                                                                                                                                                                                                                                                                                                                          
                                               Ackermark et al. (2017) \[[@b41-jos-2019-02103]\]                      Disability                       Correlated with depressive symptoms (ρ=--0.343, *P*=0.001)                                                                                                                                                                                                      Yes
                                               Fertl et al. (1999) \[[@b51-jos-2019-02103]\]                          Reduced working capacity         Depression was more frequent in patients with reduced working capacity (*P*\<0.001).                                                                                                                                                                            No
  Biomarkers                                                                                                                                                                                                                                                                                                                                                                                                           
                                               Colledge et al. (2017) \[[@b13-jos-2019-02103]\]                       Hair cortisol level              Correlated with depressive symptoms (r=0.56)                                                                                                                                                                                                                    No
                                               Kreitschmann-Andermahr et al. (2007) \[[@b47-jos-2019-02103]\]         Basal cortisol value             Correlated with (r=--0.56, *P*\<0.01) and predicted depression (R^2^=0.30)                                                                                                                                                                                      Yes
                                               Alfieri et al. (2008) \[[@b17-jos-2019-02103]\]                        APOE-ε4                          Correlated with depressive symptoms (*P*\<0.05)                                                                                                                                                                                                                 No

OR, odds ratio; SAH, subarachnoid hemorrhage; CESD, Center for Epidemiologic Studies Depression; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; IES, Impact of Event Scale; APOE-ε4, apolipoprotein E ε4.

###### 

Summary of studies reporting impact of depression after subarachnoid hemorrhage on patients' lives

  Study                        Outcomes                                           Associations with outcomes            Confounders adjusted for                                                                                          
  ---------------------------- -------------------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Work                                                                                                                                                                                                                                    
                               Buunk et al. (2015) \[[@b30-jos-2019-02103]\]      Unemployment                          Unemployed patients had higher level of depression (HADS-D score: 4.98±4.57 vs. 3.01±3.41, *P*\<0.05).            None
                               Hedlund et al. (2011) \[[@b62-jos-2019-02103]\]    Unemployment                          Patients with a lifetime history of depression has higher rate of unemployment (χ^2^=5.5, *P*=0.019).             None
                               Boerboom et al. (2016) \[[@b24-jos-2019-02103]\]   Unemployment                          Depression predicted unemployment (OR, 1.126; 95% CI, 1.01--1.25; *P*=0.031)                                      Age, gender, cognitive function
                               Carter et al. (2000) \[[@b61-jos-2019-02103]\]     Unemployment                          Depression predicted unemployment (OR, 10.5; 95% CI, 3.3--33.7; *P*\<0.001)                                       Age, physical disability, neurological deficits
                               Fertl et al. (1999) \[[@b51-jos-2019-02103]\]      Reduced work capacity                 Depression was more common amongst patients with reduced work capacity (*P*\<0.001).                              None
  HRQOL and related outcomes                                                                                                                                                                                                              
                               Passier et al. (2012) \[[@b16-jos-2019-02103]\]    HRQOL                                 Depressive symptoms did not predict HRQOL.                                                                        Gender, education level, aneurysm location, discharge destination, cognitive function, level of impairment
                               Taufique et al. (2016) \[[@b52-jos-2019-02103]\]   HRQOL                                 Depression predicted poor HRQOL (OR, 2.3; 95% CI, 1.7--7.3; *P*=0.02).                                            Age, ethnicity, education level, history of anxiety, neurological assessments, dmission CT scan grading, complications
                               Vetkas et al. (2013) \[[@b59-jos-2019-02103]\]     HRQOL                                 Depressive symptoms were related to lower mental health component score of HRQOL (β=--8.8, SE=1.6, *P*\<0.05).    Anxiety, agoraphobia-panic, fatigue and insomnia symptoms
                               Meyer et al. (2010) \[[@b44-jos-2019-02103]\]      HRQOL                                 Depression predicted poor HRQOL (β=--1.80, 95% CI, --4.01 to --0.06, *P*=0.03).                                   Gender, marital status, education, clinical status on admission, functional disability
                               King et al. (2009) \[[@b37-jos-2019-02103]\]       HRQOL                                 Depressive symptoms was correlated with lower HRQOL (ρ=--0.52, *P*\<0.001).                                       Disability, anxiety symptoms
                               Brand et al. (2015) \[[@b65-jos-2019-02103]\]      HRQOL                                 No association                                                                                                    None
                               Fertl et al. (1999) \[[@b51-jos-2019-02103]\]      Satisfaction in life                  Depressive symptoms was correlated with lower satisfaction in life (r=--0.46, *P*\<0.01).                         None
  Functional outcomes                                                                                                                                                                                                                     
                               Wong et al. (2013) \[[@b56-jos-2019-02103]\]       Functional outcomes                   Depression predicted unfavorable outcome (OR, 1.24; 95% CI, 1.1--1.3; *P*\<0.001).                                Cognitive deficits, neurological deficits
                               Buunk et al. (2018) \[[@b26-jos-2019-02103]\]      Functional outcomes                   No association                                                                                                    Fatigue and anxiety symptoms
                               Hütter et al. (1995) \[[@b20-jos-2019-02103]\]     Functional impairment in daily life   Depression was correlated with functional impairment in daily life (r=0.63, *P*\<0.001).                          None
  Other outcomes                                                                                                                                                                                                                          
                               Buunk et al. (2015) \[[@b30-jos-2019-02103]\]      Leisure and social activities         HADS-D score correlated with problems in leisure (r=0.45, *P*\<0.01) and social (r=0.51, *P*\<0.01) activities.   None
                               Carter et al. (2000) \[[@b61-jos-2019-02103]\]     Reintegration to normal living        Depression predicted reintegration to normal living (OR, 15.2; 95% CI, 6.4--36.2; *P*\<0.001).                    Age, physical disability, neurological deficits
                               Passier et al. (2011) \[[@b15-jos-2019-02103]\]    Fatigue                               Depressive symptoms predicted severity of fatigue (F=4.10, *P*=0.046).                                            Level of impairment

HADS-D, Hospital Anxiety Depression Scale-depression subscale; OR, odd ratio; HRQOL, health-related quality of life; CT, computed tomography; SE, standard error.
